Overall rank by patents
#42,758
Across all tracked assignees
USPTO PatentsView assignee record - 6 granted patents across 9 technology areas, active 2022–2024. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: Y02E (REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION).
The verdict
Sceye holds 6 US patents across 9 technology areas, rank #42,758 of 50,000 tracked assignees.
Sceye Sa has been granted 6 US utility patents between 2022 and 2024, placing Sceye Sa at rank #42,758 across all assignees tracked by PlainPatent. This portfolio spans 9 distinct Cooperative Patent Classification (CPC) subclasses, averaging 14.2 claims per patent with primary concentration in Y02E (REDUCTION OF GREENHOUSE GAS [GHG] EMISSIONS, RELATED TO ENERGY GENERATION, TRANSMISSION OR DISTRIBUTION). As a Foreign Corporation, Sceye Sa is one of the more focused assignees in the PatentsView dataset. By volume, Sceye sits between Satco Products, Inc. (6 patents, rank #42,754) and SCI Pharmtech Inc. (6 patents, rank #42,762) - the closest US assignees by grant volume. The composite Innovation Score of 45.8/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Historical data spans 2022 through 2024, with 6 total grants over that period. Velocity comparisons require five years of historical filings to calibrate. The Foreign Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Sceye Sa's 14.2 average claims per patent sits within the typical range for solid legal coverage without excessive prosecution cost, while concentration in 9 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Sceye Sa against peers pursuing similar technology classes.
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
SATCO PRODUCTS, INC.
6 patents
SAVIO MACCHINE TESSILI S.P.A.
6 patents
SBI ALAPHARMA CANADA, INC.
6 patents
SBYKE USA LLC
6 patents
SCHNELLER LLC
6 patents
SCHOOL JUDICIAL PERSON IKUTOKU GAKUEN
6 patents
SCHOTTEL GMBH
6 patents
SCI PHARMTECH INC.
6 patents
SCEYE SA
6 patents
What this shows Sceye holds 6 patents at rank #42,758, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #42,758 in granted patent volume.
Other assignees with the most granted patents in Sceye's primary technology class.
Sceye's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
46 Top 22% higher than 78% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2022–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2022 | 1 | 16.7% |
| 2023 | 2 | 33.3% |
| 2024 | 3 | 50.0% |
Top 9 of 9 technology areas
Overall rank by patents
#42,758
Across all tracked assignees
45.8 out of 100
How to use this portfolio
Sceye's 6 grants land it in the top 22% by Innovation Score, but volume alone doesn't tell you where the strength sits.
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.